SNY — Sanofi

Sanofi Q4 and Full Year 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Q4 Sales: EUR 11.3 billion, up 13.3% year-over-year.
• Full Year Sales: EUR 43.6 billion, representing 9.9% growth at constant exchange rates.
• Business EPS: Increased by 15% (12.2% excluding share buybacks).
• Gross Margin: Expanded by 1.8 percentage points to 77.5%.
• Operating Income: Increased by 11.9%, with a business operating income margin of 27.8%.
• Free Cash Flow: Returned to strong levels at EUR 8.1 billion, 18.5% of sales.
• Net Debt: Slight increase to EUR 11 billion, maintaining a conservative net debt-to-EBITDA ratio of 0.8x.

2. Strategic Updates and Business Highlights

• R&D Focus: Transitioning to an R&D-driven, AI-powered biopharma model.
• New Product Launches: Achieved EUR 5.7 billion in sales from new launches, including ALTUVIIIO (EUR 1.2 billion), Qfitlia, Wayrilz, and Nuvaxovid.
• Dupixent Performance: EUR 15.7 billion in annual sales, with a 30% increase in patient adoption across multiple indications.
• Vaccine Leadership: Full year vaccine sales reached EUR 7.9 billion, with strong performances in influenza and RSV.
• Acquisitions: Completed the acquisition of Vicebio and proposed acquisition of Dynavax Technologies to enhance vaccine portfolio.

3. Forward Guidance and Outlook

• 2026 Sales Growth: Expected to be in the high single-digit range, with business EPS growth anticipated to slightly exceed sales growth.
• Long-term Outlook: Aiming for profitable growth over the next five years, with a commitment to sustainable value creation and shareholder returns.
• Capital Allocation: Plans for a EUR 1 billion share buyback in 2026, following the completion of a EUR 5 billion program in 2025.

4. Bad News, Challenges, or Points of Concern

• R&D Reimbursement Decline: Anticipated decrease of EUR 400 million in R&D reimbursement from Regeneron, impacting 2026 earnings.
• Vaccine Sales Decline: Expected slight decline in vaccine sales in 2026, with uncertainties related to U.S. pediatric immunization schedule changes.
• Market Competition: Increased competition in immunology and potential challenges from new entrants in the market, particularly for Dupixent.
• Regulatory Challenges: Tolebrutinib's path forward in the U.S. remains uncertain, with no clear regulatory approval anticipated.

5. Notable Q&A Insights

• Dupixent Market Penetration: Continued strong growth in new indications (CSU and COPD), with expectations for normalization in growth rates moving forward.
• Beyfortus Dynamics: Positive performance in 2025, but uncertainty remains regarding U.S. market dynamics due to recent immunization schedule changes.
• Pipeline Developments: Positive feedback on amlitelimab, with ongoing discussions about its potential and market positioning.
• Business Development Strategy: Sanofi remains focused on strategic acquisitions, particularly in immunology, while maintaining a disciplined approach to capital allocation.

Overall, Sanofi reported a robust performance in 2025, driven by strong sales growth and strategic product launches, while navigating challenges related to reimbursement and competitive pressures. The outlook for 2026 remains positive, with a focus on sustainable growth and innovation.